Open Access
E3S Web Conf.
Volume 185, 2020
2020 International Conference on Energy, Environment and Bioengineering (ICEEB 2020)
Article Number 03042
Number of page(s) 9
Section Medical Biology and Medical Signal Processing
Published online 01 September 2020
  1. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020. [Google Scholar]
  2. Coronavirus death rate 2020 [Available from:,. [Google Scholar]
  3. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020. [Google Scholar]
  4. F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. [Google Scholar]
  5. Countries where Coronavirus has spread 2020 [Available from: s-where-coronavirus-has-spread/ [Google Scholar]
  6. Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020 [Available from: briefing-on-covid-19—11-march-2020 [Google Scholar]
  7. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–44. [Google Scholar]
  8. Liu Y, Gayle AA, Wilder-Smith A, Rocklov J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2)pii: taaa021. [Google Scholar]
  9. Zarghampoor F, Azarpira N, Khatami SR, et al. Improved translation efficiency of therapeutic mRNA. Gene. 2019;707:231–38. [Google Scholar]
  10. Wang, F., Kream, R., & Stefano, G. (2020, May 5). An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. Retrieved July 09, 2020, from [Google Scholar]
  11. World Health Organization (WHO) Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization; coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it [Google Scholar]
  12. Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol. 2020 [Epub ahead of print] [Google Scholar]
  13. Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. Science. 2020 [Epub ahead of print] [Google Scholar]
  14. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of the SARS-CoV-2 by full length human ACE2. Science. 2020;367(6485):1444–48. [Google Scholar]
  15. Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–52. [Google Scholar]
  16. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A. 2005;102(39):14040–5. [CrossRef] [PubMed] [Google Scholar]
  17. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, et al. Evidence for camel- to-human transmission of MERS coronavirus. N Engl J Med. 2014;370(26):2499–505. [Google Scholar]
  18. characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio. 2012;3(6). [Google Scholar]
  19. Han HJ, Wen HL, Zhou CM, Chen FF, Luo LM, Liu JW, et al. Bats as reservoirs of severe emerging infectious diseases. Virus Res. 2015;205:1–6. [Google Scholar]
  20. Fung TS, Liu DX. Human Coronavirus: Host- Pathogen Interaction. Annu Rev Microbiol. 2019;73:529–57. [Google Scholar]
  21. Thanh Le T, Andreadakis Z, Kumar A, Gomez Roman R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 [Google Scholar]
  22. Yamey G, Schaferhoff M, Hatchett R, Pate M, Zhao F, McDade KK. Ensuring global access to COVID-19 vaccines. Lancet. 2020. [Google Scholar]
  23. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol. 2010;28(6):573–9. [CrossRef] [PubMed] [Google Scholar]
  24. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509–17. [CrossRef] [PubMed] [Google Scholar]
  25. Lee J, Arun Kumar S, Jhan YY, Bishop CJ. Engineering DNA vaccines against infectious diseases. Acta Biomater. 2018;80:31–47. [CrossRef] [PubMed] [Google Scholar]
  26. Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020. [Google Scholar]
  27. [Google Scholar]
  28. Karch CP, Burkhard P. Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem Pharmacol. 2016;120:1–14. [CrossRef] [PubMed] [Google Scholar]
  29. McClean S. Prospects for subunit vaccines: Technology advances resulting in efficacious antigens requires matching advances in early clinical trial investment. Hum Vaccin Immunother. 2016;12(12): 3103–6. [CrossRef] [PubMed] [Google Scholar]
  30. Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol. 2013;25(2):152–9. [Google Scholar]
  31. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA- based vaccines. Vaccine. 2012;30(30):4414–8. [CrossRef] [PubMed] [Google Scholar]
  32. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511–20. [CrossRef] [PubMed] [Google Scholar]
  33. Lee LYY, Izzard L, Hurt AC. A Review of DNA Vaccines Against Influenza. Front Immunol.2018;9:1568. [CrossRef] [PubMed] [Google Scholar]
  34. Vitelli A, Folgori A, Scarselli E, Colloca S, Capone S, Nicosia A. Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane. Expert Rev Vaccines. 2017;16(12): 1241–52. [CrossRef] [PubMed] [Google Scholar]
  35. Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol. 2016;41:47–54. [CrossRef] [PubMed] [Google Scholar]
  36. Wu L, Zhang Z, Gao H, Li Y, Hou L, Yao H, et al. Open-label phase I clinical trial of Ad5- EBOV in Africans in China. Hum Vaccin Immunother. 2017;13(9):2078–85. [CrossRef] [PubMed] [Google Scholar]
  37. Capone S, D’Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines. 2013;12(4):379–93. [CrossRef] [PubMed] [Google Scholar]
  38. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster- randomised trial (Ebola Qa Suffit!). Lancet. 2017;389(10068):505–18. [CrossRef] [PubMed] [Google Scholar]
  39. Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12(7):1107–13. [PubMed] [Google Scholar]
  40. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020. [Google Scholar]
  41. Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2014;22(3):668–74. [CrossRef] [PubMed] [Google Scholar]
  42. Venkatraman N, Ndiaye BP, Bowyer G, Wade D, Sridhar S, Wright D, et al. Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen - ChAd3-EBO-Z followed by MVA-EBO-Z in healthy adults in the UK and Senegal. J Infect Dis. 2018. [Google Scholar]
  43. Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non- randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020. [Google Scholar]
  44. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3. [Google Scholar]
  45. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–9. [Google Scholar]
  46. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561–4. [PubMed] [Google Scholar]
  47. Wang YD, Sin WY, Xu GB, Yang HH, Wong TY, Pang XW, et al. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J Virol.2004;78(11):5612–8. [Google Scholar]
  48. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020. [Google Scholar]
  49. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22(2):72–3. [Google Scholar]
  50. Yip MS, Leung NH, Cheung CY, Li PH, Lee HH, Daeron M, et al. Antibody-dependent infection of hum [Google Scholar]
  51. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV- Infected Mice. Cell Host Microbe. 2016;19(2):181–93. [CrossRef] [PubMed] [Google Scholar]
  52. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double- inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23): 12201–15. [CrossRef] [PubMed] [Google Scholar]
  53. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019- nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742. [CrossRef] [PubMed] [Google Scholar]
  54. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019) - recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006–11. [Google Scholar]
  55. Zhou J, Fang L, Yang Z, et al. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach. FASEB J. 2019;33(12):14575–87. [CrossRef] [PubMed] [Google Scholar]
  56. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.e8. [Google Scholar]
  57. Jef Akst. COVID-19 vaccine frontrunners. The Scientist Magazine. (29 Apr 2020) Accessed 30 Apr 2020 [Google Scholar]
  58. Iavarone C, O’hagan DT, Yu D, et al. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017;16(9):871–81. [CrossRef] [PubMed] [Google Scholar]
  59. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2019;9(11):1319–30. [Google Scholar]
  60. Midoux P, Pichon C. Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines. 2015;14(2): 221–34. [CrossRef] [PubMed] [Google Scholar]
  61. Kramps T, Elbers K. Introduction to RNA Vaccines. Methods Mol Biol. 2017;1499:1–11. [CrossRef] [PubMed] [Google Scholar]
  62. Liu QH, Zhu JK, Liu ZC, et al. Assessing the Global Tendency of COVID-19 Outbreak. medRxiv 2020; published online Mar 18. [Google Scholar]
  63. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020; published online Mar 27. [Google Scholar]
  64. Zhang L, Zhang F, Yu W, et al. Antibody Responses against SARS Coronavirus are Correlated with Disease Outcome of Infected Individuals. J Med Virol. 2006; 78:1–8. [CrossRef] [PubMed] [Google Scholar]
  65. Wu F, Wang AJ, Liu M, et al. Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and their Implications. medRxiv 2020; published online Mar 30. [Google Scholar]
  66. Zhao JJ, Yuan Q, Wang HY, et al. Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. medRxiv 2020; published online Mar 2. [Google Scholar]
  67. Zhang BC, Zhou XY, Zhu CL, et al. Immune Phenotyping Based on Neutrophil-to-lymphocyte Ratio and IgG Predicts Disease Severity and Outcome for Patients with COVID-19. medRxiv 2020; published online Mar 12. [Google Scholar]
  68. COVID-19 vaccine trial 2020 [Available from: [Google Scholar]
  69. Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One. 2012;7(7):e40385. [CrossRef] [PubMed] [Google Scholar]
  70. van Doremalen N, Lambe T, Sebastian S, Bushmaker T, Fischer R, Feldmann F, et al. A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. PLoS Negl Trop Dis. 2019;13(6):e0007462. [CrossRef] [PubMed] [Google Scholar]
  71. Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon RL, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults. Vaccine. 2020;38(4):779–89. [CrossRef] [PubMed] [Google Scholar]
  72. Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, et al. Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. EBioMedicine. 2018;29:146–54. [CrossRef] [PubMed] [Google Scholar]
  73. A clinical trial to determine the safety and immunogenicity of healthy candidate MERS- CoV vaccine (MERS002) 2019 [Available from: [Google Scholar]
  74. Safety and immunogenicity of a candidate MERS-CoV vaccine (MERS001) 2019 [Available from: [Google Scholar]
  75. Study of a Candidate COVID-19 vaccine (COV001) 2020 [Available from: vid-19+vaccine&draw=2&rank=1 [Google Scholar]
  76. Lim B, Lee K. Stability of the osmoregulated promoter-derived proP mRNA is posttranscriptionally regulated by RNase III in Escherichia coli. J Bacteriol. 2015;197(7):1297–305. [CrossRef] [PubMed] [Google Scholar]
  77. Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol. 2017;1499:109–21. [CrossRef] [PubMed] [Google Scholar]
  78. Knights AJ, Nuber N, Thomson CW, et al. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother. 2009;58(3):325–38. [CrossRef] [PubMed] [Google Scholar]
  79. Ohto T, Konishi M, Tanaka H, et al. Inhibition of the inflammatory pathway enhances both the in vitro and in vivo transfection activity of exogenous in vitro-transcribed mRNAs delivered by lipid nanoparticles. Biol Pharm Bull. 2019;42(2):299–302. [CrossRef] [PubMed] [Google Scholar]
  80. Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326–34. [CrossRef] [PubMed] [Google Scholar]
  81. Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543(7644):248–51. [PubMed] [Google Scholar]
  82. WHO. DRAFT landscape of COVID- 19 candidate vaccines 2020 [Available from: [Google Scholar]
  83. Boodman, E. 2020. Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals. STAT, without-usual-animal-testing/(accessed April 3, 2020). [Google Scholar]
  84. Nicole Lurie, MD, MSPH, Melanie Saville, M.D., Richard Hatchett, MD,et al;) Developing Covid-19 Vaccines at Pandemic Speed. The New England Journal of Medicine. (30 Mar 2020). [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.